Celldex Therapeutics (CLDX) Receivables (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly Receivables came in at $230000.0 in Q1 2026, down 78.38% year-on-year from $1.1 million in Q1 2025, and down 88.59% quarter-over-quarter from $2.0 million in Q4 2025.
Celldex Therapeutics (CLDX) Receivables (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $230000.0 for Q1 2026.
- On a quarterly basis, Receivables fell 78.38% year-over-year to $230000.0 in Q1 2026; TTM through Mar 2026 was $230000.0, a 78.38% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 187.86% from the prior year.
- Receivables slipped to $230000.0 in Q1 2026 per CLDX's latest filing, from $2.0 million in the prior quarter.
- Across five years, Receivables topped out at $2.7 million in Q1 2024 and bottomed at $90000.0 in Q2 2025.
- The 5-year median for Receivables is $252000.0 (2023), against an average of $763933.3.
- Across the five-year window, Receivables surged 1200.0% in 2024 and sank 94.13% in 2025, its largest moves.
- Year by year, Receivables stood at $189000.0 in 2022, then surged by 33.33% to $252000.0 in 2023, then surged by 177.78% to $700000.0 in 2024, then soared by 187.86% to $2.0 million in 2025, then plunged by 88.59% to $230000.0 in 2026.
- Per Business Quant, the three latest CLDX Receivables figures stand at $230000.0 (Q1 2026), $2.0 million (Q4 2025), and $90000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn | 230,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 230,000.00 |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 90,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 852,000.00 |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Sep 30, 2023 | 252,000.00 |
| Jun 30, 2023 | 118,000.00 |
| Mar 31, 2023 | 1.31 Mn |
| Sep 30, 2022 | 189,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 243,000.00 |
| Dec 31, 2021 | 172,000.00 |
| Sep 30, 2021 | 197,000.00 |
| Jun 30, 2021 | 496,000.00 |
| Mar 31, 2021 | 1.83 Mn |
| Dec 31, 2020 | 1.80 Mn |